Integrated Nanotherapeutics

Integrated Nanotherapeutics (INT) is a preclinical-stage biotechnology company focused on developing antigen-specific immune tolerance therapies to address the root causes of autoimmune diseases. The company utilizes a proprietary, modular lipid nanoparticle (LNP) drug delivery platform capable of incorporating a wide range of small molecules and nucleic acids. This technology enables the co-delivery of diverse drug modalities, including mRNA, with tunable release profiles. By leveraging this versatile platform, INT aims to treat conditions such as Type 1 Diabetes, Multiple Sclerosis, and various allergies.

Headquartered in Burnaby, British Columbia, the company is led by a scientific team with extensive experience in LNP science, having contributed to the development of five approved LNP-based drugs. INT actively collaborates with academic and industry partners to advance its preclinical pipeline, including a lead program, INT-101, for Type 1 Diabetes. The company’s efforts are supported by various grants and collaborations, such as with Breakthrough T1D, as they work toward clinical translation of their immune-tolerizing therapeutics. Through its precision-engineered delivery systems, the organization strives to unlock new therapeutic potential for diverse compounds and improve patient outcomes.